Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2010 2
2011 5
2012 5
2013 5
2014 6
2015 5
2016 6
2017 5
2018 8
2019 2
2020 9
2021 10
2022 13
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue: A Story About the Need for Proficiency Testing for High-Quality Molecular Biomarker Reporting in Precision Medicine.
Schmidt C, Stöhr R, Dimitrova L, Beckmann MW, Rübner M, Fasching PA, Denkert C, Lehmann U, Vollbrecht C, Haller F, Hartmann A, Erber R. Schmidt C, et al. Among authors: stohr r. J Mol Diagn. 2024 Apr 30:S1525-1578(24)00088-6. doi: 10.1016/j.jmoldx.2024.04.003. Online ahead of print. J Mol Diagn. 2024. PMID: 38697471
Machine Learning-Supported Diagnosis of Small Blue Round Cell Sarcomas Using Targeted RNA Sequencing.
Schlieben LD, Carta MG, Moskalev EA, Stöhr R, Metzler M, Besendörfer M, Meidenbauer N, Semrau S, Janka R, Grützmann R, Wiemann S, Hartmann A, Agaimy A, Haller F, Ferrazzi F. Schlieben LD, et al. Among authors: stohr r. J Mol Diagn. 2024 May;26(5):387-398. doi: 10.1016/j.jmoldx.2024.02.002. Epub 2024 Feb 21. J Mol Diagn. 2024. PMID: 38395409 Free article.
Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center.
Tögel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K, Moskalev EA, Stöhr R, Agaimy A, Reis A, Wullich B, Mackensen A, Pavel M, Beckmann MW, Hartmann A, Fietkau R, Meidenbauer N, Haller F, Spoerl S. Tögel L, et al. Among authors: stohr r. Cancers (Basel). 2023 Dec 18;15(24):5892. doi: 10.3390/cancers15245892. Cancers (Basel). 2023. PMID: 38136436 Free PMC article.
Evaluation of FGFR Alteration Status in Urothelial Tumors.
Bahlinger V, Eckstein M, Hartmann A, Stöhr R. Bahlinger V, et al. Among authors: stohr r. Methods Mol Biol. 2023;2684:283-291. doi: 10.1007/978-1-0716-3291-8_17. Methods Mol Biol. 2023. PMID: 37410241
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
Claps F, van de Kamp MW, Mayr R, Bostrom PJ, Shariat SF, Hippe K, Bertz S, Neuzillet Y, Sanders J, Otto W, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Trombetta C, Eckstein M, Mertens LS, Burger M, Soorojebally Y, Wullich B, Bartoletti R, Radvanyi F, Pavan N, Sirab N, Mir MC, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Bussani R, Allory Y, van Rhijn BWG. Claps F, et al. Among authors: stohr r. BJU Int. 2023 Aug;132(2):170-180. doi: 10.1111/bju.15984. Epub 2023 Feb 20. BJU Int. 2023. PMID: 36748180
Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.
Schrenk KG, Weschenfelder W, Spiegel C, Agaimy A, Stöhr R, Hartmann A, Gaßler N, Drescher R, Freesmeyer M, Malouhi A, Bürckenmeyer F, Aschenbach R, Teichgräber U, Kögler C, Vogt M, Hofmann GO, Hochhaus A. Schrenk KG, et al. Among authors: stohr r. J Cancer Res Clin Oncol. 2023 Aug;149(9):5493-5496. doi: 10.1007/s00432-022-04496-y. Epub 2022 Dec 5. J Cancer Res Clin Oncol. 2023. PMID: 36469155 Free PMC article.
In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study.
Lorusso R, De Piero ME, Mariani S, Di Mauro M, Folliguet T, Taccone FS, Camporota L, Swol J, Wiedemann D, Belliato M, Broman LM, Vuylsteke A, Kassif Y, Scandroglio AM, Fanelli V, Gaudard P, Ledot S, Barker J, Boeken U, Maier S, Kersten A, Meyns B, Pozzi M, Pedersen FM, Schellongowski P, Kirali K, Barrett N, Riera J, Mueller T, Belohlavek J; EuroECMO-COVID Study Group. Lorusso R, et al. Lancet Respir Med. 2023 Feb;11(2):151-162. doi: 10.1016/S2213-2600(22)00403-9. Epub 2022 Nov 16. Lancet Respir Med. 2023. PMID: 36402148 Free PMC article.
Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma.
Kloker LD, Calukovic B, Benzler K, Golf A, Böhm S, Günther S, Horger M, Haas S, Berchtold S, Beil J, Carter ME, Ganzenmueller T, Singer S, Agaimy A, Stöhr R, Hartmann A, Duell T, Mairhofer S, Fohrer F, Reinmuth N, Zender L, Lauer UM. Kloker LD, et al. Among authors: stohr r. Front Oncol. 2022 Oct 27;12:995744. doi: 10.3389/fonc.2022.995744. eCollection 2022. Front Oncol. 2022. PMID: 36387105 Free PMC article.
82 results